Abiopharma

Gilead - Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

Pfizer Inc. - Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Incyte presenteert eerste gegevens over zijn TGFβR2×PD-1-gerichte bispecifieke antilichaam (INCA33890) en zijn selectieve G12D-gemuteerde KRAS (INCB161734)-remmer tijdens het congres van de European Society of Medical Oncology (ESMO) in 2025

Q & M Dental Group (Singapore) Limited - Announcement

Incyte präsentiert erste Daten für seinen TGFβR2×PD-1-gerichteten bispezifischen Antikörper (INCA33890) und seinen selektiven Inhibitor des G12D-mutierten KRAS (INCB161734) auf dem Kongress der European Society of Medical Oncology (ESMO) 2025

New Form 4 - Natera, Inc. Filed: 2025-07-24 AccNo: 0001415889-25-020278 Size: 14 KB

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Absci Announces Pricing of Public Offering of Common Stock